Welcome to the Heart Centre Biobank

A provincial and international research network aimed at improving outcomes in heart disease through enhanced prevention and treatment.
Happier Children, Healthier Hearts.
ted rogers centre for heart research
labatt family heart centre

Children can have different types of heart diseases, such as cardiomyopathies, which can be childhood onset or congenital. Congenital heart defects occur in one out of every 100 newborns, but the causes of most forms of congenital heart defects are not known. Today, advances in technology permit us to sequence the entire genome of an individual. This has opened up new opportunities to do large-scale studies to find out which genes cause heart disease in children and adults.

This multi-centre research network has resulted in the establishment of the first Ontario province-wide biorepository and registry of patients with congenital and other forms of heart disease.

Today, this is now one of the biggest childhood heart disease biobank registries in the world, with over 10,200 participants!

The network provides a resource to investigators to study the genetic and environmental causes of heart defects and other diseases through the study of DNA, tissue, skin, and blood samples from affected individuals.

The ultimate goal is to develop better ways to diagnose, prevent, and treat disease in children and adults and to improve their overall health and well-being. This exciting initiative, the first of its kind in Ontario, is an example of leveraging our expertise to promote international collaboration and innovation in human disease research.

Seema Mital, MD

Principal Investigator, Heart Centre Biobank Registry

Heart Centre Biobank Video

If you are interested in participating, check out this short video that will tell you all about our study! Feel free to contact us using the form here if you have any questions or would like to find out more.

Our Biobank Family

  • ENROLLMENT

    Our enrollment is trending up as we continue to recruit new and retain existing participants. Our patient population grows on average by 8% each year. We currently have over 10,200 participants.

  • DATA

    We continue to support research at SickKids, across Canada and together with researchers from across the world. We have supported 70 research studies with the specimens and data that you have donated to the biobank.

  • FAMILY PARTICIPATION

    We recognize the importance of studying not just the child with disease but parents to help us determine if the finding is new or passed down. We now target the enrolment of parents for every individual we enrol. If you are a parent who has not yet participated and would like to, please contact us! Participation can also be coordinated by mail.

Recent Highlights

Common Genetic Variants Contribute to Risk of Transposition of the Great Arteries

Tetralogy of Fallot (TOF) and Transposition of the great arteries (TGA) are the leading causes of cyanotic congenital heart disease i.e. “blue” babies. Through an international collaboration in patients with TGA, it was identified that several common variants near the gene, WNT5A, may explain up to 25% of the risk of inheriting this heart condition. This work suggests that TGA can be the result of several gene variants rather than a single gene variant.

Read full publication
Rare variants in KDR, encoding VEGF Receptor 2, are associated with tetralogy of Fallot

Rare genetic variants in KDR, encoding the vascular endothelial growth factor receptor 2 (VEGFR2), have been reported in patients with tetralogy of Fallot (TOF). Exome sequencing, large-scale genetic studies, and cell-based assays were conducted to explore the role of KDR genetic variation in the etiology of TOF. A 46-fold enrichment of protein-truncating variants (PTVs) in TOF cases compared to controls was identified. The findings in this study shed light on the role of VEGF signaling in TOF and justify consideration of KDR screening in TOF patients in a clinical diagnostic setting.

Read full publication
PRecIsion Medicine in CardiomyopathY (PRIMaCY)

Hypertrophic cardiomyopathy is the leading cause of sudden cardiac death in adolescents and young adults. Despite the availability of implantable cardioverter-defibrillators (ICD) as a life-saving intervention, the lack of precision in predicting sudden death risk hampers timely ICDs in at-risk patients resulting in deaths that could have been prevented.

PRIMaCY has developed an eHealth clinical decision support tool that generates an individualized 5-year risk prediction for sudden cardiac death (SCD) for each patient. The primary goal is to implement the PRIMaCY tool in hospital information systems for use by physicians as a point of care tool, to evaluate the effectiveness of the tool in adherence to clinical practice guidelines, and to evaluate how it influences patient/family counseling. Click the link below to explore the PRIMaCY SCD risk calculator website.

Go to primacy scd risk calculator
Machine Learning Identifies Clinical and Genetic Factors Associated With Anthracycline Cardiotoxicity in Pediatric Cancer Survivors

Medical advances have helped children with cancer survive into adulthood and live healthy lives. However some children can suffer from cardiac side-effects of chemotherapy, in particular, to a class of drugs called anthracyclines which are used to treat almost 50% of cancers. This can manifest as reduced heart function, or even heart failure, years to decades after exposure. Unfortunately our ability to predict who is at risk for developing cardiac side-effects has been limited.

We performed exome sequencing in close to 300 pediatric cancer survivors enrolled in a multi-center international study. We identified rare variants in several genes that influenced which children develop cardiotoxicity. Manipulating these genes experimentally with drugs or compounds was able to protect heart cells from cardiotoxicity. Additionally, using machine learning, we developed an integrated clinical and genetic model that was superior to a clinical only model in predicting who is at risk for cardiotoxicity. In the future, this knowledge could be used by physicians to decide which child should or should not be exposed to anthracyclines, which child should be closely monitored for cardiac side-effects, and which child should get cardio-protective drugs that target their unique genetic factors. This will bring precision medicine one step closer to helping childhood cancer survivors.

Read full publication
A Validated Model for Sudden Cardiac Death Risk Prediction in Pediatric Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy is a genetic disease that causes thickening and stiffening of heart muscle and abnormal heart rhythm. It is the most common cause of sudden cardiac death in adolescents and young adults. Sudden death can be prevented through timely use of a life-saving device in the form of an implantable cardioverter-defibrillator (ICD). However, many ICDs are implanted in children at low risk who do not need them which exposes them to unnecessary complications from the device.

Through an international collaboration, we developed a risk prediction model that includes factors that are unique to a pediatric population to identify children at high risk for sudden death. By providing an individual risk score for their patient, it will help physicians to engage patients in shared decision making for ICD insertion. Successful use of this tool may increase appropriate use of ICD in those at high risk for sudden death, thereby increasing lives saved.

Read full publication

Contact Us

For any questions, or to find out more, please get in touch with us at anytime.